DaVita Debt to Equity Ratio 2012-2026 | DVA
Current and historical debt to equity ratio values for DaVita (DVA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. DaVita debt/equity for the three months ending March 31, 2026 was 0.00.
| DaVita Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $17.98B | $-0.48B | -37.74 |
| 2025-12-31 | $17.85B | $-0.37B | -47.77 |
| 2025-09-30 | $17.86B | $-0.30B | -58.71 |
| 2025-06-30 | $17.60B | $-0.11B | -163.02 |
| 2025-03-31 | $17.13B | $-0.01B | -2613.79 |
| 2024-12-31 | $16.89B | $0.40B | 42.66 |
| 2024-09-30 | $16.92B | $0.59B | 28.84 |
| 2024-06-30 | $16.18B | $0.85B | 19.03 |
| 2024-03-31 | $16.30B | $1.13B | 14.39 |
| 2023-12-31 | $15.65B | $1.24B | 12.58 |
| 2023-09-30 | $15.55B | $1.38B | 11.27 |
| 2023-06-30 | $15.75B | $1.21B | 13.06 |
| 2023-03-31 | $15.71B | $1.02B | 15.40 |
| 2022-12-31 | $16.05B | $0.88B | 18.33 |
| 2022-09-30 | $16.26B | $0.70B | 23.16 |
| 2022-06-30 | $16.33B | $0.78B | 21.06 |
| 2022-03-31 | $16.07B | $1.02B | 15.78 |
| 2021-12-31 | $16.19B | $0.94B | 17.29 |
| 2021-09-30 | $16.31B | $1.33B | 12.28 |
| 2021-06-30 | $16.35B | $1.46B | 11.18 |
| 2021-03-31 | $16.21B | $1.43B | 11.31 |
| 2020-12-31 | $15.42B | $1.57B | 9.84 |
| 2020-09-30 | $15.29B | $1.75B | 8.72 |
| 2020-06-30 | $16.97B | $2.33B | 7.27 |
| 2020-03-31 | $15.46B | $2.13B | 7.25 |
| 2019-12-31 | $14.99B | $2.32B | 6.46 |
| 2019-09-30 | $14.94B | $2.51B | 5.95 |
| 2019-06-30 | $15.69B | $4.24B | 3.70 |
| 2019-03-31 | $18.52B | $4.09B | 4.53 |
| 2018-12-31 | $15.20B | $3.91B | 3.89 |
| 2018-09-30 | $15.33B | $4.03B | 3.80 |
| 2018-06-30 | $14.95B | $4.49B | 3.33 |
| 2018-03-31 | $14.16B | $4.78B | 2.96 |
| 2017-12-31 | $14.09B | $4.89B | 2.88 |
| 2017-09-30 | $14.04B | $4.97B | 2.83 |
| 2017-06-30 | $14.07B | $5.27B | 2.67 |
| 2017-03-31 | $14.05B | $5.34B | 2.63 |
| 2016-12-31 | $13.91B | $4.85B | 2.87 |
| 2016-09-30 | $13.81B | $5.12B | 2.70 |
| 2016-06-30 | $13.73B | $4.96B | 2.77 |
| 2016-03-31 | $13.59B | $4.92B | 2.76 |
| 2015-12-31 | $13.43B | $5.08B | 2.64 |
| 2015-09-30 | $13.70B | $5.19B | 2.64 |
| 2015-06-30 | $13.60B | $5.35B | 2.54 |
| 2015-03-31 | $13.20B | $5.17B | 2.55 |
| 2014-12-31 | $12.26B | $5.36B | 2.29 |
| 2014-09-30 | $12.95B | $5.15B | 2.51 |
| 2014-06-30 | $12.97B | $4.96B | 2.62 |
| 2014-03-31 | $12.56B | $4.84B | 2.60 |
| 2013-12-31 | $12.49B | $4.61B | 2.71 |
| 2013-09-30 | $12.39B | $4.44B | 2.79 |
| 2013-06-30 | $12.17B | $4.28B | 2.84 |
| 2013-03-31 | $12.46B | $3.96B | 3.15 |
| 2012-12-31 | $12.10B | $3.92B | 3.09 |
| 2012-09-30 | $8.15B | $2.67B | 3.05 |
| 2012-06-30 | $6.75B | $2.51B | 2.69 |
| 2012-03-31 | $6.76B | $2.40B | 2.81 |
| 2011-12-31 | $6.64B | $2.27B | 2.93 |
| 2011-09-30 | $6.62B | $2.08B | 3.18 |
| 2011-06-30 | $6.25B | $1.95B | 3.21 |
| 2011-03-31 | $6.19B | $2.14B | 2.90 |
| 2010-12-31 | $6.08B | $2.04B | 2.98 |
| 2010-09-30 | $5.25B | $2.38B | 2.21 |
| 2010-06-30 | $5.22B | $2.36B | 2.22 |
| 2010-03-31 | $5.37B | $2.32B | 2.32 |
| 2009-12-31 | $5.36B | $2.19B | 2.45 |
| 2009-09-30 | $5.40B | $2.14B | 2.53 |
| 2009-06-30 | $5.39B | $2.06B | 2.62 |
| 2009-03-31 | $5.31B | $1.92B | 2.76 |
| 2008-12-31 | $5.46B | $1.83B | 2.99 |
| 2008-09-30 | $5.27B | $1.91B | 2.76 |
| 2008-06-30 | $5.27B | $1.78B | 2.96 |
| 2008-03-31 | $5.19B | $1.80B | 2.89 |
| 2007-12-31 | $5.21B | $1.73B | 3.01 |
| 2007-09-30 | $5.15B | $1.63B | 3.17 |
| 2007-06-30 | $5.17B | $1.50B | 3.45 |
| 2007-03-31 | $5.18B | $1.35B | 3.83 |
| 2006-12-31 | $5.25B | $1.25B | 4.21 |
| 2006-09-30 | $5.20B | $1.15B | 4.53 |
| 2006-06-30 | $5.30B | $1.04B | 5.08 |
| 2006-03-31 | $5.23B | $0.96B | 5.43 |
| 2005-12-31 | $5.43B | $0.85B | 6.38 |
| 2005-09-30 | $2.10B | $0.77B | 2.71 |
| 2005-06-30 | $2.07B | $0.69B | 3.01 |
| 2005-03-31 | $2.03B | $0.62B | 3.29 |
| 2004-12-31 | $1.99B | $0.52B | 3.80 |
| 2004-09-30 | $1.98B | $0.45B | 4.37 |
| 2004-06-30 | $1.67B | $0.47B | 3.53 |
| 2004-03-31 | $1.66B | $0.39B | 4.25 |
| 2003-12-31 | $1.64B | $0.31B | 5.34 |
| 2003-09-30 | $1.79B | $0.25B | 7.13 |
| 2003-06-30 | $1.89B | $0.16B | 11.92 |
| 2003-03-31 | $1.87B | $0.11B | 16.75 |
| 2002-12-31 | $1.71B | $0.07B | 24.27 |
| 2002-09-30 | $1.72B | $0.05B | 35.30 |
| 2002-06-30 | $1.67B | $0.11B | 14.73 |
| 2002-03-31 | $1.17B | $0.50B | 2.35 |
| 2001-12-31 | $1.16B | $0.50B | 2.30 |
| 2001-09-30 | $1.18B | $0.48B | 2.46 |
| 2001-06-30 | $1.26B | $0.43B | 2.94 |
| 2001-03-31 | $1.24B | $0.39B | 3.19 |
| 2000-12-31 | $1.25B | $0.35B | 3.57 |
| 2000-09-30 | $1.34B | $0.33B | 4.05 |
| 2000-06-30 | $1.54B | $0.32B | 4.80 |
| 2000-03-31 | $1.69B | $0.33B | 5.10 |
| 1999-12-31 | $1.73B | $0.33B | 5.30 |
| 1999-09-30 | $1.72B | $0.48B | 3.56 |
| 1999-06-30 | $1.63B | $0.48B | 3.39 |
| 1999-03-31 | $1.54B | $0.51B | 3.00 |
| 1998-12-31 | $1.43B | $0.48B | 2.98 |
| 1998-09-30 | $1.30B | $0.45B | 2.88 |
| 1998-06-30 | $1.18B | $0.42B | 2.81 |
| 1998-03-31 | $1.07B | $0.41B | 2.62 |
| 1997-12-31 | $0.42B | $0.27B | 1.54 |
| 1997-09-30 | $0.29B | $0.26B | 1.12 |
| 1997-06-30 | $0.24B | $0.25B | 0.94 |
| 1997-03-31 | $0.15B | $0.24B | 0.60 |
| 1996-12-31 | $0.14B | $0.23B | 0.62 |
| 1996-09-30 | $0.12B | $0.20B | 0.57 |
| 1996-06-30 | $0.09B | $0.20B | 0.43 |
| 1996-03-31 | $0.14B | $0.09B | 1.62 |
| 1995-12-31 | $0.08B | $0.08B | 0.98 |
| 1995-09-30 | $0.00B | 0.00 | |
| 1995-06-30 | $0.00B | 0.00 | |
| 1995-03-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $10.023B | $13.643B |
| DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Quest Diagnostics (DGX) | United States | $21.197B | 19.44 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |